Newly-released Intravenous Iron Drugs market analysis report by Future Market Insights shows that global sales of the Intravenous Iron Drugs Market in 2021 were held at US$ 2.6 billion. With 8.5%, the projected market growth from 2022 to 2032 is expected to be higher than the historical growth.
The Intravenous Iron Drugs Market is projected to witness an absolute dollar opportunity of US$ 3.5 billion. The prevalence of chronic kidney disease (CKD), Inflammatory Bowel Disease (IBD), and cancer have increased the demand for intravenous iron medicines for the treatment of subsequent Iron Deficiency Anaemia.
| Attribute | Details |
|---|---|
| Global Intravenous Iron Drugs Market (2022) | US$ 2.8 billion |
| Global Intravenous Iron Drugs Market (2032) | US$ 6.3 billion |
| Global Intravenous Iron Drugs Market CAGR (2022 to 2032) | 8.5% |
| USA Intravenous Iron Drugs Market (2022) | US$ 922.7 million |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Intravenous Iron Drugs market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Intravenous Iron Drugs Market increased at around 8.1% CAGR, wherein, the region North America held a significant share in the global market.
Iron is a component of haemoglobin, which transports oxygen in the blood and also allows for the creation of red blood cells. Anaemia is a diagnosed condition in which an individual is lacking in the body's iron needs. Anaemia symptoms include weariness and loss of energy, unusually quick heartbeat when exercising, difficulties concentrating, pale skin and dizziness, sleeplessness, and cramping.
According to a recent survey done by the Vitamin and Mineral Nutrition Information System (VMNIS), around 40% of mothers and children in poor nations are anaemic. As a result, the market is expected to grow at a CAGR of 8.5% over the next ten years.
Anaemia is one of the most frequent blood illnesses nowadays. Anaemia affects an estimated 3 million people in the United States, according to the National Heart, Lung, and Blood Institute. The rising incidence of target illnesses such as rheumatoid arthritis, autoimmune diseases, renal issues, cancer, liver disorders, thyroid diseases, and inflammatory bowel disease is a significant factor driving the expansion of the intravenous iron medication market.
As per National Kidney Foundation, the two primary causes of CKD are diabetes and hypertension. Also, according to the report, the chronic renal disease affects approximately 10% of the worldwide population, with over 2 million people needing dialysis on a daily basis. The bulk of all these people is often observed in nations such as Italy, the United States, Germany, Japan, and Brazil.
A significant number of people who have the disease are unaware of it until severe symptoms appear. The frequency of chronic kidney disease is expected to rise in developing economies such as India and China, implying an increase in the elderly population in the future years. With the increasing incidence of these disorders, there is a greater demand for intravenous iron medicines.
One of the biggest disadvantages of oral iron medications is the possibility of significant side effects. Digestive issues such as stomach pains, constipation, lack of appetite, nausea, and vomiting are common side effects of oral iron medications. Convulsions, shallow or quick breathing, exhaustion or weakness, fatigue, pale complexion, and bluish skin or fingernails can all result from an overdose of oral iron medications.
Intravenous iron medications, on the other hand, have been demonstrated to promote iron intake by the body, allowing Erythropoiesis-stimulating Agents (ESAs) to act more effectively in lowering anemic conditions. Other benefits of intravenous iron medications include heart health preservation and the potential to be utilized by dialysis patients, particularly those undergoing hemodialysis. These negative effects are thus expected to assist the changeover to intravenous iron medications, boosting their use during the projection period.
Principal Consultant
The market in Asia Pacific is expected to swell at a significant pace of 8.6% from 2022 to 2032. This may be ascribed to the availability of prominent players in the Asia Pacific, as well as the strengthening of healthcare infrastructure with the growing government efforts. Furthermore, the prevalence of IDA in rising economies such as China and India has aided industry expansion.
Besides, the market in Europe is anticipated to increase significantly throughout the forecast year as a result of the growing research and commercialization of new products, the acceptance of advanced medications, and the region's rising incidence of malignancy.
The United States dominated the North American Intravenous Iron Drugs Market, which is expected to reach US$ 2.2 billion by 2032 and will increase at a CAGR of 9.3% CAGR during the forecast period. The reimbursement and technological advancement facilities are advantageous factors for market growth in the United States.
The growing geriatric population is a key driver of market expansion in the country. According to USA Census Bureau projections, the number of Americans aged 65 and up is expected to grow from 52 million in 2018 to nearly 95 million by 2060. Furthermore, the share of people aged 65 and up is expected to rise from 16% to 23%.
Its dominance is also due to the region's rising rates of cancer, chronic renal disease, and gastrointestinal ailments. Furthermore, an increase in awareness of women's health and a surge in the frequency of celiac disease are the other factors boosting the market in the country.
The market for intravenous iron drugs in the United Kingdom stood at US$ 115 million in 2021. The market in the country is projected to swell at a CAGR of 8.2% during the forecast period to reach a valuation of US$ 278 million by 2032. The market in the country is expected to register an absolute dollar opportunity of US$ 151 million from 2022 to 2032.
The market in Japan is likely to expand with an absolute dollar opportunity of US$ 128 million from 2022 to 2032. The market in the country is expected to reach a valuation of US$ 233 million by 2032 growing at a CAGR of 8.2% during the forecast period.
In South Korea, the market is projected to reach a valuation of US$ 127 million by 2032, growing from US$ 66 million in 2022. With an absolute dollar opportunity of US$ 61 million, the market in the country is expected to register a CAGR of 6.7% during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In 2020, the market for intravenous iron drugs led the market for intravenous medicines for chronic kidney disease, accounting for 30% of the total in 2021. This large market may be due to the fact that chronic kidney disease (CKD) and intravenous iron therapies are intensively used by CKD patients. IDA is a prevalent complication in CKD patients. It is uncommon in the early stages of renal illness; nevertheless, it happens as the disease progresses and kidney function declines.
Anaemia is caused by a decrease in the amount of Red Blood Cells (RBCs) in CKD patients. The growth in CKD cases has resulted in a large increase in the number of IDA patients. The conventional therapy for people with dialysis and non-dialysis-related CKD is intravenous iron. Dialysis is used to treat anaemia and end-stage renal failure.
Due to the increasing incidence of cancer and the consequent increase in the number of IDA cases, the market revenue through cancer application is expected to grow at the fastest CAGR throughout the projection period.
IDA affects a considerable proportion of cancer patients. Blood cancer, bone cancer, cervical cancer, colon cancer, and prostate cancer are all common cancers associated with anaemia. According to the NCBI, lung and breast cancers have the highest rate of anaemia among solid tumours. Hematologic cancers, such as leukaemia, lymphoma, and multiple myeloma, create abnormal blood cells, which weaken the immune system and cause anaemia. Chemotherapy and radiation therapy are two cancer therapies that cause anaemia in individuals.
Some of the key players in the global Intravenous Iron Drugs market include Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; Shield Therapeutics Plc; AbbVie Inc., Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; and Shield Therapeutics Plc among others.
Some of the recent developments in the Intravenous Iron Drugs Market are:
The global market is worth more than US$ 2.6 billion at present.
The value of the Intravenous Iron Drugs Market is projected to increase at a CAGR of around 8.5% from 2022 to 2032.
The value of the Intravenous Iron Drugs Market increased at a CAGR of around 8.1% from 2017 to 2021.
The top 5 countries driving demand for the Intravenous Iron Drugs market are the USA, China, the United Kingdom, Japan, and South Korea.
The USA market for Intravenous Iron Drugs is projected to expand at a CAGR of around 9.3% from 2022 to 2032.
The key companies in intravenous iron drugs market are AMAG Pharmaceuticals, AbbVie Inc., Daiichi Sankyo Company Ltd., Sanofi, and Vifor Pharma Management Ltd.
1. Executive Summary | Intravenous Iron Drugs Market 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Demand 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ million) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background and Foundation Data Points 4.1. Global Market (US$ million) 4.2. Market Opportunity Assessment (US$ million) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Global Market Growth 4.5.3. Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Market Demand Analysis 2017 to 2021 and Forecast, 2022 to 2032 6.1. Historical Market Analysis, 2017 to 2021 6.2. Current and Future Market Projections, 2022 to 2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ million) Analysis, 2017 to 2021 7.2. Current and Future Market Value (US$ million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ million) Analysis By Product Type, 2017 to 2021 8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Product Type, 2022 to 2032 8.3.1. Iron Dextran 8.3.2. Iron Sucrose 8.3.3. Ferric carboxymaltose 8.3.4. Other Product Types 8.4. Market Attractiveness Analysis By Product Type 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ million) Analysis By Indication, 2017 to 2021 9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Indication, 2022 to 2032 9.3.1. Chronic Kidney Disease 9.3.2. Inflammatory Bowel Disease 9.3.3. Cancer 9.3.4. Other Applications 9.4. Market Attractiveness Analysis By Indication 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 10.1. Introduction 10.2. Historical Market Size (US$ million) Analysis By Region, 2017 to 2021 10.3. Current Market Size (US$ million) & Analysis and Forecast By Region, 2022 to 2032 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. Asia Pacific 10.3.5. Middle East and Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032 11.1. Introduction 11.2. Pricing Analysis 11.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032 11.4.1. By Country 11.4.1.1. The USA 11.4.1.2. Canada 11.4.1.3. Rest of North America 11.4.2. By Product Type 11.4.3. By Indication 11.5. Market Attractiveness Analysis 11.5.1. By Country 11.5.2. By Product Type 11.5.3. By Indication 12. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032 12.4.1. By Country 12.4.1.1. Brazil 12.4.1.2. Mexico 12.4.1.3. Rest of Latin America 12.4.2. By Product Type 12.4.3. By Indication 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Product Type 12.5.3. By Indication 13. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032 13.4.1. By Country 13.4.1.1. Germany 13.4.1.2. France 13.4.1.3. The United Kingdom 13.4.1.4. Italy 13.4.1.5. Benelux 13.4.1.6. Nordic Countries 13.4.1.7. Rest of Europe 13.4.2. By Product Type 13.4.3. By Indication 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Product Type 13.5.3. By Indication 14. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032 14.4.1. By Country 14.4.1.1. China 14.4.1.2. Japan 14.4.1.3. South Korea 14.4.1.4. Rest of Asia Pacific 14.4.2. By Product Type 14.4.3. By Indication 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Product Type 14.5.3. By Indication 15. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 15.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032 15.4.1. By Country 15.4.1.1. GCC Countries 15.4.1.2. South Africa 15.4.1.3. Turkey 15.4.1.4. Rest of Middle East and Africa 15.4.2. By Product Type 15.4.3. By Indication 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Product Type 15.5.3. By Indication 16. Key Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.1.1. Market Value Proportion Analysis, By Key Countries 16.1.2. Global Vs. Country Growth Comparison 16.2. US Market Analysis 16.2.1. Value Proportion Analysis by Market Taxonomy 16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.2.2.1. By Product Type 16.2.2.2. By Indication 16.3. Canada Market Analysis 16.3.1. Value Proportion Analysis by Market Taxonomy 16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.3.2.1. By Product Type 16.3.2.2. By Indication 16.4. Mexico Market Analysis 16.4.1. Value Proportion Analysis by Market Taxonomy 16.4.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.4.2.1. By Product Type 16.4.2.2. By Indication 16.5. Brazil Market Analysis 16.5.1. Value Proportion Analysis by Market Taxonomy 16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.5.2.1. By Product Type 16.5.2.2. By Indication 16.6. Germany Market Analysis 16.6.1. Value Proportion Analysis by Market Taxonomy 16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.6.2.1. By Product Type 16.6.2.2. By Indication 16.7. France Market Analysis 16.7.1. Value Proportion Analysis by Market Taxonomy 16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.7.2.1. By Product Type 16.7.2.2. By Indication 16.8. Italy Market Analysis 16.8.1. Value Proportion Analysis by Market Taxonomy 16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.8.2.1. By Product Type 16.8.2.2. By Indication 16.9. BENELUX Market Analysis 16.9.1. Value Proportion Analysis by Market Taxonomy 16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.9.2.1. By Product Type 16.9.2.2. By Indication 16.10. The United Kingdom Market Analysis 16.10.1. Value Proportion Analysis by Market Taxonomy 16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.10.2.1. By Product Type 16.10.2.2. By Indication 16.11. Nordic Countries Market Analysis 16.11.1. Value Proportion Analysis by Market Taxonomy 16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.11.2.1. By Product Type 16.11.2.2. By Indication 16.12. China Market Analysis 16.12.1. Value Proportion Analysis by Market Taxonomy 16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.12.2.1. By Product Type 16.12.2.2. By Indication 16.13. Japan Market Analysis 16.13.1. Value Proportion Analysis by Market Taxonomy 16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.13.2.1. By Product Type 16.13.2.2. By Indication 16.14. South Korea Market Analysis 16.14.1. Value Proportion Analysis by Market Taxonomy 16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.14.2.1. By Product Type 16.14.2.2. By Indication 16.15. GCC Countries Market Analysis 16.15.1. Value Proportion Analysis by Market Taxonomy 16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.15.2.1. By Product Type 16.15.2.2. By Indication 16.16. South Africa Market Analysis 16.16.1. Value Proportion Analysis by Market Taxonomy 16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.16.2.1. By Product Type 16.16.2.2. By Indication 16.17. Turkey Market Analysis 16.17.1. Value Proportion Analysis by Market Taxonomy 16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032 16.17.2.1. By Product Type 16.17.2.2. By Indication 16.17.3. Competition Landscape and Player Concentration in the Country 17. Market Structure Analysis 17.1. Market Analysis by Tier of Companies 17.2. Market Concentration 17.3. Market Share Analysis of Top Players 17.4. Market Presence Analysis 17.4.1. By Regional footprint of Players 17.4.2. Product footprint by Players 18. Competition Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Competition Deep Dive 18.3.1. VIFOR PHARMA MANAGEMENT LTD. 18.3.1.1. Overview 18.3.1.2. Product Portfolio 18.3.1.3. Sales Footprint 18.3.1.4. Strategy Overview 18.3.2. AMAG PHARMACEUTICALS 18.3.2.1. Overview 18.3.2.2. Product Portfolio 18.3.2.3. Sales Footprint 18.3.2.4. Strategy Overview 18.3.3. DAIICHI SANKYO COMPANY, LTD. 18.3.3.1. Overview 18.3.3.2. Product Portfolio 18.3.3.3. Sales Footprint 18.3.3.4. Strategy Overview 18.3.4. SANOFI S.A. 18.3.4.1. Overview 18.3.4.2. Product Portfolio 18.3.4.3. Sales Footprint 18.3.4.4. Strategy Overview 18.3.5. PHARMACOSMOS A/S 18.3.5.1. Overview 18.3.5.2. Product Portfolio 18.3.5.3. Sales Footprint 18.3.5.4. Strategy Overview 18.3.6. SHIELD THERAPEUTICS PLC 18.3.6.1. Overview 18.3.6.2. Product Portfolio 18.3.6.3. Sales Footprint 18.3.6.4. Strategy Overview 18.3.7. ABBVIE INC. 18.3.7.1. Overview 18.3.7.2. Product Portfolio 18.3.7.3. Sales Footprint 18.3.7.4. Strategy Overview 19. Assumptions and Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Intravenous Iron Drugs Market
